Alpha Fusion, an Osaka, Japan-based company bringing bringing “Targeted Alpha Therapy (TAT) using Astatine (At-211)” to cancer patients worldwide, raised ¥1.02 Billion in Series B funding.
The round was led by SBI Investment Co., Ltd. and OSAKA University Venture Capital, with participation from new investors.
The company intends to use the funds to expand its R&D efforts and prepare clinical trials, enhance its supply chain for GMP-grade clinical trial drug production domestically and internationally, and further expand its team.
Led by CEO Sunao Fujioka, Alpha Fusion is a startup dedicated to bringing “targeted alpha therapy (TAT) using Astatine (At-211)” to cancer patients worldwide. It is advancing its pipeline and building a highly efficient supply chain using cyclotrons in collaboration with partners across the globe.
FinSMEs
09/10/2024